文献速递肾小球疾病

首个南亚前瞻性IgA肾病队列的流行病学、基线特征与进展风险

Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort.
PubMed 文献 · Kidney Int Rep · 2020-12-07

GRACE-IgANI是首个南亚前瞻性IgA肾病队列,纳入201例活检确诊的成人患者,中位随访30个月。基线时高血压最常见,34%有肾病范围蛋白尿,肾活检显示活动性病变少而节段性硬化和小管间质纤维化多。两种工具预测中位5年ESKD绝对风险19.8%,联合终点风险35.5%。

要点

  • 南亚IgA肾病常见高血压和肾病范围蛋白尿,但活动性病变少、慢性化病变多。
  • 男性患者eGFR相对保留且蛋白尿水平较低,但节段性硬化和小管间质纤维化仍常见。
  • 预测5年ESKD风险中位19.8%,联合终点风险35.5%,进展风险可观。

核心结论

  • 该南亚IgA肾病队列预测的进展风险相当高。

研究设计与样本

  • GRACE-IgANI为前瞻性纵向观察队列,2015年3月至2017年9月纳入201例活检确诊的原发性IgA肾病成人患者,至2020年4月30日中位随访30个月(IQR 16-39)。

主要发现

  • 最常见临床表现为高血压伴或不伴蛋白尿,34%存在肾病范围蛋白尿,尽管肾活检前 lead time 小于10个月。
  • 肾活检显示活动性肾小球病变不成比例地少,而节段性硬化病变和小管间质纤维化过度代表,常与相对保留的eGFR和低蛋白尿水平共存,尤其在男性。
  • 使用两种风险预测工具计算,中位5年ESKD绝对风险为19.8%(IQR 2.7-57.4),中位5年进展至eGFR下降50%或ESKD联合终点风险为35.5%。

临床怎么用

  • 对南亚IgA肾病患者应重视高血压和蛋白尿管理,并评估肾活检中的慢性化病变。
  • 可借助风险预测工具评估个体5年进展风险,以指导监测和治疗强度。

局限性

  • 随访时间尚短,预测风险基于基线工具计算,需长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glomerular Research And Clinical Experiments-IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgAN cohort with protocolized follow-up and extensive biosample collection. Here we report the baseline clinical, biochemical, and histopathologic characteristics of GRACE IgANI and calculate baseline risk of progression for the cohort. METHODS: 201 incident adults with kidney biopsy-proven primary IgAN were recruited into GRACE-IgANI between March 2015 and September 2017. As of April 30, 2020, the cohort had completed a median follow-up of 30 months (interquartile range [IQR] 16-39). RESULTS: The commonest clinical presentation in GRACE IgANI was hypertension, with or without proteinuria, and nephrotic-range proteinuria was present in 34%, despite <10 months of lead time to kidney biopsy. The GRACE-IgANI kidney biopsy data demonstrated a disproportionate absence of active glomerular lesions and overrepresentation of segmental sclerosing lesions and tubulointerstitial fibrosis at presentation, often coexistent with relatively well-preserved estimated glomerular filtration rate (eGFR) and low levels of proteinuria, especially in males. Baseline risk of progression was calculated for each evaluable patient using 2 different risk prediction tools. The median 5-year absolute risk of end-stage kidney disease (ESKD) was 19.8% (IQR 2.7-57.4) and median 5-year risk of progression to the combined endpoint of 50% decline in eGFR or ESKD was 35.5% using the 2 tools. CONCLUSIONS: The predicted risk of progression in this cohort was considerable. Over the next 5 years, we will dissect the pathogenic pathways that underlie this severe South Asian IgAN phenotype.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Alexander S, Varughese S, Franklin R, et al. Epidemiology, baseline characteristics and risk of progression in the first South-Asian prospective longitudinal observational IgA nephropathy cohort. Kidney Int Rep. 2020. PMID: 33615067. doi:10.1016/j.ekir.2020.11.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。